Skip to Main Content

Paper Details

Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.
Clin Infect Dis
29
2022
Adults, Bcl-2, CD38, CD4, CD4+, CD4+ T-cells, HIV, HLADR, IL-6, Jak, Jak 1/2, PWH, Participants, Ruxolitinib, efavirenz, end, inflammation, participant, participants, people, plasma, reservoir, ruxolitinib, sCD14
Author NameAffiliation
Vincent C MarconiEmory University School of Medicine
Vincent C Marconi
Vincent C MarconiAtlanta Veterans Affairs Medical Center
Vincent C MarconiEmory University Rollins School of Public Health
Steven G DeeksUniversity of California san francisco
Steven G DeeksUniversity of California san francisco
Michael M LedermanCase Western Reserve University
Peter W HuntUniversity of California san francisco
Rafick-Pierre SekalyCase Western Reserve University
  • 1 - 9

Datasets

Release 1.2